AtriCure, Inc. ATRC
65.53 USD +5.12 (+8.48%)
At closeNov 4, 2026, 4:21 PM EST
65.71 +0.18 +0.27%
After hours · Nov 4, 4:21 PM ET
58.00 Day range 66.02
25.36 52-week range 66.02
- YTD
- +65.65%
- 1 year
- +100.09%
Analyst view
Consensus: buy
Buy
Price target (mean) 57.56 -12.2% downside
Now 65.53
- Target (low)
- 36.00
- Target (mean)
- 57.56
- Target (high)
- 68.00
Ratings (0m) 10 7 buy · 3 hold · 0 sell
- Strong buy3
- Buy4
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 10
- 1 month ago 10
- 2 months ago 10
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.08184 | 0.04 – 0.13 | 0.06 | +36.4% | 159.83M | +13.8% | 8 |
| Next quarter | -0.005 | -0.05 – 0.07 | 0.00 | 0.0% | 158.60M | +12.3% | 6 |
| Current year | 0.2999 | 0.25 – 0.42 | -0.11 | +372.6% | 606.26M | +13.4% | 8 |
| Next year | 0.42543 | 0.21 – 0.64 | 0.2999 | +41.9% | 680.45M | +12.2% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Nov 4, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Nov 4, 2026 | Needham | Maintained | Buy | Buy |
| Nov 4, 2026 | BTIG | Maintained | Buy | Buy |
| Oct 21, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Oct 12, 2026 | BTIG | Maintained | Buy | Buy |
| Oct 2, 2026 | Freedom Capital Markets | Downgrade | Buy | Hold |
| Sep 2, 2026 | Needham | Maintained | Buy | Buy |
| Aug 27, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 24, 2026 | BTIG | Maintained | Buy | Buy |
| Jul 28, 2026 | UBS | Maintained | Buy | Buy |
| May 6, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Feb 18, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Feb 18, 2026 | UBS | Maintained | Buy | Buy |
| Feb 18, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Feb 18, 2026 | Oppenheimer | Downgrade | Outperform | Perform |
| Feb 18, 2026 | BTIG | Reiterated | Buy | Buy |
| Feb 12, 2026 | Needham | Reiterated | Buy | Buy |
| Dec 16, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 30, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Jul 30, 2025 | Needham | Maintained | Buy | Buy |
| Apr 30, 2025 | BTIG | Maintained | Buy | Buy |
| Apr 30, 2025 | UBS | Maintained | Buy | Buy |
| Apr 30, 2025 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Apr 30, 2025 | Needham | Maintained | Buy | Buy |
| Apr 2, 2025 | Citizens Capital Markets | Reiterated | Market Outperform | Market Outperform |
| Mar 28, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 27, 2025 | BTIG | Maintained | Buy | Buy |
| Mar 27, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Mar 27, 2025 | Needham | Reiterated | Buy | Buy |
